The new efficacy rate of the coronavirus vaccine CoronaVac, developed by the Chinese company Sinovac, has been announced.
In the study conducted in Chile with 10.2 million people, the vaccine showed 65.9% efficacy rate in preventing COVID-19, 87.5% in preventing hospitalization, 90.3% in preventing intensive care, and 86.3% in preventing death.
After the study, which was carried out between Feb. 2 and May 1, 2021, the vaccine effectively prevented COVID-19, including severe illness and death, consistent with the results of Phase 2 trials.
While the study was the most comprehensive research on the vaccine developed by Sinovac, 45,000 people were examined in the study conducted in Brazil last month, and it was stated that the vaccine prevented deaths by 95% in 5 weeks after its administration.
While the number of cases increased due to the delta variant in the world, a Sinovac spokesperson said the company’s vaccine was effective against variants as well.
Sinovac said that administering two doses of the vaccine followed by a booster dose can rapidly elicit a stronger and more durable antibody reaction to the delta variant.
